Investor Relations
Key Figures
| IFRS (in EURm except otherwise stated) | 2016 | 2015 |
| Revenues | 2536.6 | 1950.1 |
| Adjusted EBITDA | 479.6 | 360.8 |
| Reported EBITDA | 461.1 | 345.0 |
| Basic EPS (EUR) | 10.88 | 5.71 |
| Net Operating Cash Flow | 371.8 | 291.1 |
Outstanding shares:
17,042,641 (at 31.08.2017)
Dividend
The AGM of 20 April 2017 approved the payment of a dividend of EUR 2.00 per share for the year 2016 compared to EUR 1.45 for the previous year.
The dividend dates are as follows:
- ex-dividend date: 29 June 2017
- record date: 30 June 2017
- payment date: 3rd July 2017
Financial News
- 18.09.2017Eurofins to expand its presence in North America with the acquisition of EAG Laboratories
- 07.09.2017Eurofins Genoma introduces GeneSafeTM – the first non-invasive prenatal test that screens for single-gene disorders
- 30.08.2017Eurofins reports solid H1 2017 results with 15.6% revenue growth on the back of an organic growth of about 6% and over 35 acquisitions signed year-to-date representing over EUR 300m pro forma annual revenues
- 10.08.2017Eurofins strengthens its footprint in food and agroscience testing in Japan with new acquisitions
- 31.07.2017Eurofins expands its offering and footprint in drug discovery services with the acquisition of DiscoverX
Annual Reports
Next publication: 30th August 2017, First Half-Year 2017 Financial Results
Order a hard copy of the 2016 Annual Report
Research Paper by Prof. Brooks
OBSAAR prospectus in French only